Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy
drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton
therapy for the treatment of locally advanced pancreatic cancer. You will receive proton
therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy
on each Monday of those three weeks.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore